Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms

[1]  M. Cazzola,et al.  Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. , 2015, Blood.

[2]  C. Pecquet,et al.  Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis , 2014 .

[3]  A. Tefferi,et al.  The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. , 2014, Blood.

[4]  E. Solary,et al.  Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution , 2014, Leukemia.

[5]  M. Cazzola,et al.  Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. , 2014, Blood.

[6]  P. Arguin.  Case definition: postartemisinin delayed hemolysis. , 2014, Blood.

[7]  F. J. Novo,et al.  Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling , 2014, Leukemia.

[8]  M. Cazzola,et al.  From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. , 2014, Blood.

[9]  T. Golub,et al.  Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. , 2014, Blood.

[10]  Christian Beisel,et al.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. , 2014, Blood.

[11]  A. Balduini,et al.  The importance of calcium in the regulation of megakaryocyte function , 2014, Haematologica.

[12]  M. Cazzola,et al.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. , 2014, Blood.

[13]  U. Laforenza,et al.  Enhanced Expression of Stim, Orai, and TRPC Transcripts and Proteins in Endothelial Progenitor Cells Isolated from Patients with Primary Myelofibrosis , 2014, PloS one.

[14]  P. Guglielmelli,et al.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. , 2014, Blood.

[15]  R. Tiu,et al.  Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca2+: some mechanistic and therapeutic implications , 2014, Blood Cancer Journal.

[16]  F. Passamonti,et al.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons , 2014, Leukemia.

[17]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[18]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[19]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[20]  M. Severgnini,et al.  Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. , 2013, Blood.

[21]  T. Barbui,et al.  Cardiovascular events and intensity of treatment in polycythemia vera. , 2013, The New England journal of medicine.

[22]  T. Barbui,et al.  Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). , 2012, Blood.

[23]  A. Balduini,et al.  In Vitro Megakaryocyte Differentiation and Proplatelet Formation in Ph-Negative Classical Myeloproliferative Neoplasms: Distinct Patterns in the Different Clinical Phenotypes , 2011, PloS one.

[24]  M. Cazzola,et al.  Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms , 2011, Haematologica.

[25]  M. Cazzola,et al.  Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. , 2011, Blood.

[26]  M. Cazzola,et al.  p53 lesions in leukemic transformation. , 2011, The New England journal of medicine.

[27]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[28]  M. Cazzola,et al.  A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications , 2010, Leukemia.

[29]  A. Parekh.  Store-operated CRAC channels: function in health and disease , 2010, Nature Reviews Drug Discovery.

[30]  D. Birnbaum,et al.  Mutations of ASXL1 gene in myeloproliferative neoplasms , 2009, Leukemia.

[31]  A. Balduini,et al.  Proplatelet formation in heterozygous Bernard‐Soulier syndrome type Bolzano , 2009, Journal of thrombosis and haemostasis : JTH.

[32]  P. Campbell,et al.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment , 2008, Leukemia.

[33]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[34]  M. Nehls,et al.  An EF hand mutation in Stim1 causes premature platelet activation and bleeding in mice. , 2007, The Journal of clinical investigation.

[35]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[36]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[37]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[38]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[39]  J. Putney,et al.  Store-operated calcium channels. , 2005, Physiological reviews.

[40]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[41]  M. Berridge,et al.  Calcium signalling: dynamics, homeostasis and remodelling , 2003, Nature reviews. Molecular cell biology.

[42]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[43]  T. Pozzan,et al.  Delayed activation of the store-operated calcium current induced by calreticulin overexpression in RBL-1 cells. , 1998, Molecular biology of the cell.

[44]  R. Penner,et al.  The Store-Operated Calcium Current ICRAC: Nonlinear Activation by InsP3 and Dissociation from Calcium Release , 1997, Cell.

[45]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[46]  J. D. van der Walt,et al.  European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.